Title

Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown

UMMS Affiliation

Lysosomal Disorders Treatment and Research Program; Department of Neurology, Department of Psychiatry

Publication Date

2021-04-01

Document Type

Article

Disciplines

Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Health Services Administration | Infectious Disease | Nervous System Diseases | Nutritional and Metabolic Diseases | Virus Diseases

Abstract

Early in the course of the novel coronavirus disease 2019 (COVID-19) pandemic, the rare disease community anticipated that patients with lysosomal and other metabolic disorders would be at increased risk for poor disease outcomes and mortality from the SARS-CoV-2 virus.

Keywords

COVID-19 pandemic, Gaucher disease, lysosomal and metabolic disorders, rare diseases

DOI of Published Version

10.1016/j.ymgme.2021.02.005

Source

Ginns EI, Ryan E, Sidransky E. Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown. Mol Genet Metab. 2021 Apr;132(4):213-214. doi: 10.1016/j.ymgme.2021.02.005. Epub 2021 Feb 24. PMID: 33676819; PMCID: PMC7903902. Link to article on publisher's site

Journal/Book/Conference Title

Molecular genetics and metabolism

Related Resources

Link to Article in PubMed

PubMed ID

33676819

Share

COinS